<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR28">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Taylor-Stokes</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Mitra</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Waller</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Gibson</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Milligan</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Iyer</surname>
    <given-names>S</given-names>
   </name>
  </person-group>
  <article-title>Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: results from the IRIS study</article-title>
  <source>Breast</source>
  <year>2019</year>
  <volume>43</volume>
  <fpage>22</fpage>
  <lpage>27</lpage>
  <pub-id pub-id-type="doi">10.1016/j.breast.2018.10.009</pub-id>
  <?supplied-pmid 30391832?>
  <pub-id pub-id-type="pmid">30391832</pub-id>
 </element-citation>
</ref>
